Milestone's shares dive after FDA again rejects drug for abnormal heart rhythm

Ayisha Sharma

News Reporter

Milestone Pharmaceuticals’ nasal spray failed for a second time to secure US approval to treat an arrhythmia disorder called paroxysmal supraventricular tachycardia.

The FDA’s complete …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Milestone's shares dive after FDA again rejects drug for abnormal heart rhythm

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

Mile­stone's shares dive af­ter FDA again re­jects drug for ab­nor­mal heart rhythm

News Reporter

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Milestone's shares dive after FDA again rejects drug for abnormal heart rhythm